Myokardia, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-09-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.myokardia.com
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Phase 3
Completed
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: PlaceboDrug: mavacamten
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT03470545
- Locations
- 🇺🇸
Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Phase 2
Completed
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: mavacamtenDrug: Placebo
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03442764
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
Phase 1
Completed
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Drug: MYK-491 or placebo
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03062956
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Phase 2
Completed
- Conditions
- Left Ventricular Outflow Tract ObstructionCardiomyopathy, Hypertrophic Obstructive
- Interventions
- Drug: MYK-461
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02842242
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: MYK-461Drug: Placebo
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02480296
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Single Ascending Dose Study of MYK-461 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: MYK-461Drug: Placebo
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02356289
- Locations
- 🇬🇧
Quintles LTD, London, United Kingdom
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
Phase 1
Completed
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Drug: MYK-461
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02329184
© Copyright 2025. All Rights Reserved by MedPath